Istituto Romagnolo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAbigail linehanIstituto nazionale tumoriFoundationone cdxIstituto romagnoloInstitut gustave roussyUniversity of washingtonFox chase cancer centerFoundation medicine foundationoneFoundation medicine on twitterFoundation medicine incUniversity of texas md anderson cancer centerSan raffaele scientific instituteSan rafael universityEuropean society for medical oncology

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDino amadoriDaniele calistriIstituto romagnoloKevin puylaertBioscience laboratoryHub centersEmilia romagna regionPredictive molecular diagnostics areaManaging directorVitro diagnostic useLooking statements

Age No Barrier to Preserved QoL, Functional Recovery After Surgery for CRC

More than 70% of patients with a median age of 79 achieved both outcomes at 3-6 months

Emilia romagnaNew yorkUnited statesUniversity of rochesterCharles bankheadIstituto romagnoloAnthony loriaFergalj flemingFlavia focaTumori dino amadoriDaily livingFlemish triage risk screening toolMedpage todayClin oncol

Significant EU funding for implementing value-based cancer care at European cancer hospitals

The EU has awarded 7 MEUR to HUS Helsinki University Hospital led Consortium, which aims to unlock the full potential of real-world data collected in European cancer hospitals. This in turn will support the implementation of safer, more efficient, and personalized novel cancer therapies. “To implement value-based cancer care, real-world data on the cost-effectiveness of treatments is needed in real-time”, states the project lead, senior medical director in oncology, Johanna Mattson.

Eteläuomen läiIstituto romagnoloTumori dino amadoriNederlands kanker instituut antonRigshospitalet copenhagen university hospitalBc platformsHelsinki university hospitalUniversity hospitalStichting het nederlands kanker instituut antonSiemens healthcareInstituto portugues de oncologia

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC ( Optimizing In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ponatinib (Iclusig ) over a range of three starting doses (45mg, 30mg, 15mg) followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to prior tyrosine kinase inhibitor (TKI) therapy met its primary endpoint.

United statesUnited kingdomRachael remaly francoLuca mariniIstituto romagnoloGianantonio rostiPonatinib iclusigTumori dino amadoriChristine chiouAmerican society of clinical oncologyMillennium pharmaceuticals incTakeda pharmaceutical companyExchange commissionEuropean unionTakeda pharmaceuticals internationalHead of european medical affairs incyte